Cross Q&A: Ixazomib in Multiple Myeloma

Video

Dr Clifton Mo fields questions from the Memorial Sloan Kettering team about his presentation on IRd in relapsed/refractory multiple myeloma.

CN_FaceOff_MM_Seg03_QA
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Subscribe Now!
      Recent Videos
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      4 experts are featured in this series.
      Role of Bridging Therapy for CAR-T Patients
      4 experts are featured in this series.
      Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
      4 experts are featured in this series.
      Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
      4 experts are featured in this series.
      Overview of Process of CAR-T Therapy
      Related Content
      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

      Roman Fabbricatore
      April 1st 2025
      Article

      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma

      Russ Conroy
      March 23rd 2025
      Article

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma

      Russ Conroy
      March 19th 2025
      Article

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Tim Cortese
      March 14th 2025
      Article

      Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.